恩替卡韦治疗中慢性乙型肝炎患者分泌白细胞介素22的T细胞频数变化研究

摘要

目的:研究恩替卡韦(ETV)在慢性乙型肝炎治疗过程中患者外周血中分泌白细胞介素22(IL-22)的T细胞频数的变化.方法:在应用ETV治疗的不同时间点抽取HBV感染患者及健康对照者静脉血,分离血清及外周血单核细胞(PMBC),检测血清中乙型肝炎病毒表面标志物(HBV-M)、乙型肝炎病毒核酸定量(HBV-DNA)、丙氨酸转移酶(ALT)以及外周血中分泌IL-22的T细胞的频数.结果:应用ETV治疗后患者ALT及HBV-DNA从4周开始出现明显下降,IL-22+T细胞的频数相当于IL-22+1L-17+T细胞与IL-22+IL-17-T细胞的总数,在第4周时和基线点相比出现一个明显的升高,其后保持平稳,在36周时再次出现明显升高保持平稳至48周,在36周前低F健康对照,36周后明显高于健康对照.结论:ETV在有效抑制病毒复制的同时,IL-22+T细胞的作用和构成在HBV感染的过程中发生了变化,这种变化可能有利于肝脏炎症的减轻,但可能不利于病毒的清除.%Objective: To invetigate the feature of IL-22+T cells in chronically HBV-infected patients with enticarvir treatment.Methods:Serum and PBMCs were obtained from enrolled CHB patients and health controls and monitored for ALT,HBV DNA,HBV Markers as well as the frequency of IL-22+T cells.Results: There was a significant decrease in ALT and HBV DNA levels in patients at 4th week since the ETV therapy,the frequency of IL-22+T cells increased significantly from 4th week and increased in 36th again,higher than controls from 36 week.Conclusion: ETV efficiently suppress HBV replication,the change of frquency and composition in IL-22+T cells might attenuate hepatic inflammation but impaired clearing virus.